<DOC>
	<DOCNO>NCT02666430</DOCNO>
	<brief_summary>The aim extension study assess safety efficacy Mylan 's insulin glargine Lantus® T1DM patient .</brief_summary>
	<brief_title>Extension Study Assess Safety Efficacy Mylan 's Insulin Glargine Lantus® Type 1 Diabetes Mellitus Patients</brief_title>
	<detailed_description>This multi-center , open-label , randomized clinical extension study patient T1DM assess safety efficacy Mylan 's insulin glargine Lantus® . Patients establish diagnosis T1DM per American Diabetes Association 2014 criterion randomize Lantus® treatment arm Mylan Glargine 3001 study , complete 52-week treatment period Lantus® eligible screen MYL-1501D-3003 study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Patients complete 52week treatment period ( irrespective age completion MYLGAI3001 trial ) MYLGAI3001 trial assign Lantus® study . 2 . Patients legal representative must give write sign informed consent start protocolspecific procedure . 3 . The patient able willing comply requirement extension study protocol include 8point selfmonitoring blood glucose , completion patient diary record instruct follow recommend diet exercise plan entire duration extension study . 4 . Female patient comply follow : Female patient childbearing potential must use oral contraception two acceptable method contraception , ( e.g. , intrauterine device plus condom , spermicidal gel plus condom , diaphragm plus condom , etc . ) time randomization throughout entire study . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Postmenopausal females must menstrual bleeding least 1 year prior inclusion MYLGAI3001 study . Female patient report surgical sterilization must procedure least 6 month prior inclusion MYLGAI3001 study . All female patient childbearing potential , must negative pregnancy test result baseline ( week 0 ) clinic visit per SCHEDULE OF ACTIVITIES . If female patient male partner undergone vasectomy , vasectomy must occur 6 month prior inclusion MYLGAI3001 study . 1 . History presence medical condition disease Investigator 's opinion would place patient unacceptable risk trial participation . 2 . History clinically significant ( i.e. , significant enough alter insulin dose requirement , per Investigator ) acute bacterial , viral fungal systemic infection 4 week prior inclusion / randomization ( record collect patient history ) MYL1501D3003 extension study 3 . Patients schedule receive another investigational drug extension study period 4 . Any major elective surgery require hospitalization plan extension study period . 5 . Moderate insulin resistance , define require insulin ( Basal + Prandial ) ≥1.5 U/kg/day ( Lantus® U/kg/day Mylan 's insulin glargine IU/kg/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>